Evaluation of buspirone for relapse-prevention in adults with cocaine dependence

An efficacy trial conducted in the real world

Theresa Winhusen, Kathleen T. Brady, Maxine Stitzer, George Woody, Robert Lindblad, Frankie Kropp, Gregory Brigham, David Liu, Steven Sparenborg, Gaurav Sharma, Paul VanVeldhuisen, Bryon Adinoff, Eugene Somoza

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Cocaine dependence is a significant public health problem for which there are currently no FDA-approved medications. Hence, identifying candidate compounds and employing an efficient evaluation process is crucial. This paper describes key design decisions made for a National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN) study that uses a novel two-stage process to evaluate buspirone (60. mg/day) for cocaine-relapse prevention. The study includes pilot (N = 60) and full-scale (estimated N = 264) trials. Both trials will be randomized, double-blind, and placebo-controlled and both will enroll treatment-seeking cocaine-dependent participants engaged in inpatient/residential treatment and scheduled for outpatient treatment post-discharge. All participants will receive contingency management in which incentives are given for medication adherence as evaluated by the Medication Events Monitoring System (MEMS). The primary outcome measure is maximum days of continuous cocaine abstinence, as assessed by twice-weekly urine drug screens (UDS) and self-report, during the 15-week outpatient treatment phase. Drug-abuse outcomes include cocaine use as assessed by UDS and self-report of cocaine use, other substance use as assessed by UDS and self-report of substance use (i.e., alcohol and/or illicit drugs), cocaine bingeing, HIV risk behavior, quality of life, functioning, and substance abuse treatment attendance. Unique aspects of the study include conducting an efficacy trial in community treatment programs, a two-stage process to efficiently evaluate buspirone, and an evaluation of mediators by which buspirone might exert a beneficial effect on relapse prevention.

Original languageEnglish (US)
Pages (from-to)993-1002
Number of pages10
JournalContemporary Clinical Trials
Volume33
Issue number5
DOIs
StatePublished - Sep 2012

Fingerprint

Buspirone
Cocaine-Related Disorders
Secondary Prevention
Cocaine
Self Report
Urine
Substance-Related Disorders
Outpatients
National Institute on Drug Abuse (U.S.)
Pharmaceutical Preparations
Residential Treatment
Therapeutics
Medication Adherence
Street Drugs
Risk-Taking
Motivation
Inpatients
Public Health
Placebos
Alcohols

Keywords

  • Buspirone
  • Cocaine
  • Contingency management
  • Relapse-prevention

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Evaluation of buspirone for relapse-prevention in adults with cocaine dependence : An efficacy trial conducted in the real world. / Winhusen, Theresa; Brady, Kathleen T.; Stitzer, Maxine; Woody, George; Lindblad, Robert; Kropp, Frankie; Brigham, Gregory; Liu, David; Sparenborg, Steven; Sharma, Gaurav; VanVeldhuisen, Paul; Adinoff, Bryon; Somoza, Eugene.

In: Contemporary Clinical Trials, Vol. 33, No. 5, 09.2012, p. 993-1002.

Research output: Contribution to journalArticle

Winhusen, T, Brady, KT, Stitzer, M, Woody, G, Lindblad, R, Kropp, F, Brigham, G, Liu, D, Sparenborg, S, Sharma, G, VanVeldhuisen, P, Adinoff, B & Somoza, E 2012, 'Evaluation of buspirone for relapse-prevention in adults with cocaine dependence: An efficacy trial conducted in the real world', Contemporary Clinical Trials, vol. 33, no. 5, pp. 993-1002. https://doi.org/10.1016/j.cct.2012.05.003
Winhusen, Theresa ; Brady, Kathleen T. ; Stitzer, Maxine ; Woody, George ; Lindblad, Robert ; Kropp, Frankie ; Brigham, Gregory ; Liu, David ; Sparenborg, Steven ; Sharma, Gaurav ; VanVeldhuisen, Paul ; Adinoff, Bryon ; Somoza, Eugene. / Evaluation of buspirone for relapse-prevention in adults with cocaine dependence : An efficacy trial conducted in the real world. In: Contemporary Clinical Trials. 2012 ; Vol. 33, No. 5. pp. 993-1002.
@article{738ca75c1e0a40768aa144f45dd8c803,
title = "Evaluation of buspirone for relapse-prevention in adults with cocaine dependence: An efficacy trial conducted in the real world",
abstract = "Cocaine dependence is a significant public health problem for which there are currently no FDA-approved medications. Hence, identifying candidate compounds and employing an efficient evaluation process is crucial. This paper describes key design decisions made for a National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN) study that uses a novel two-stage process to evaluate buspirone (60. mg/day) for cocaine-relapse prevention. The study includes pilot (N = 60) and full-scale (estimated N = 264) trials. Both trials will be randomized, double-blind, and placebo-controlled and both will enroll treatment-seeking cocaine-dependent participants engaged in inpatient/residential treatment and scheduled for outpatient treatment post-discharge. All participants will receive contingency management in which incentives are given for medication adherence as evaluated by the Medication Events Monitoring System (MEMS). The primary outcome measure is maximum days of continuous cocaine abstinence, as assessed by twice-weekly urine drug screens (UDS) and self-report, during the 15-week outpatient treatment phase. Drug-abuse outcomes include cocaine use as assessed by UDS and self-report of cocaine use, other substance use as assessed by UDS and self-report of substance use (i.e., alcohol and/or illicit drugs), cocaine bingeing, HIV risk behavior, quality of life, functioning, and substance abuse treatment attendance. Unique aspects of the study include conducting an efficacy trial in community treatment programs, a two-stage process to efficiently evaluate buspirone, and an evaluation of mediators by which buspirone might exert a beneficial effect on relapse prevention.",
keywords = "Buspirone, Cocaine, Contingency management, Relapse-prevention",
author = "Theresa Winhusen and Brady, {Kathleen T.} and Maxine Stitzer and George Woody and Robert Lindblad and Frankie Kropp and Gregory Brigham and David Liu and Steven Sparenborg and Gaurav Sharma and Paul VanVeldhuisen and Bryon Adinoff and Eugene Somoza",
year = "2012",
month = "9",
doi = "10.1016/j.cct.2012.05.003",
language = "English (US)",
volume = "33",
pages = "993--1002",
journal = "Contemporary Clinical Trials",
issn = "1551-7144",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Evaluation of buspirone for relapse-prevention in adults with cocaine dependence

T2 - An efficacy trial conducted in the real world

AU - Winhusen, Theresa

AU - Brady, Kathleen T.

AU - Stitzer, Maxine

AU - Woody, George

AU - Lindblad, Robert

AU - Kropp, Frankie

AU - Brigham, Gregory

AU - Liu, David

AU - Sparenborg, Steven

AU - Sharma, Gaurav

AU - VanVeldhuisen, Paul

AU - Adinoff, Bryon

AU - Somoza, Eugene

PY - 2012/9

Y1 - 2012/9

N2 - Cocaine dependence is a significant public health problem for which there are currently no FDA-approved medications. Hence, identifying candidate compounds and employing an efficient evaluation process is crucial. This paper describes key design decisions made for a National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN) study that uses a novel two-stage process to evaluate buspirone (60. mg/day) for cocaine-relapse prevention. The study includes pilot (N = 60) and full-scale (estimated N = 264) trials. Both trials will be randomized, double-blind, and placebo-controlled and both will enroll treatment-seeking cocaine-dependent participants engaged in inpatient/residential treatment and scheduled for outpatient treatment post-discharge. All participants will receive contingency management in which incentives are given for medication adherence as evaluated by the Medication Events Monitoring System (MEMS). The primary outcome measure is maximum days of continuous cocaine abstinence, as assessed by twice-weekly urine drug screens (UDS) and self-report, during the 15-week outpatient treatment phase. Drug-abuse outcomes include cocaine use as assessed by UDS and self-report of cocaine use, other substance use as assessed by UDS and self-report of substance use (i.e., alcohol and/or illicit drugs), cocaine bingeing, HIV risk behavior, quality of life, functioning, and substance abuse treatment attendance. Unique aspects of the study include conducting an efficacy trial in community treatment programs, a two-stage process to efficiently evaluate buspirone, and an evaluation of mediators by which buspirone might exert a beneficial effect on relapse prevention.

AB - Cocaine dependence is a significant public health problem for which there are currently no FDA-approved medications. Hence, identifying candidate compounds and employing an efficient evaluation process is crucial. This paper describes key design decisions made for a National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN) study that uses a novel two-stage process to evaluate buspirone (60. mg/day) for cocaine-relapse prevention. The study includes pilot (N = 60) and full-scale (estimated N = 264) trials. Both trials will be randomized, double-blind, and placebo-controlled and both will enroll treatment-seeking cocaine-dependent participants engaged in inpatient/residential treatment and scheduled for outpatient treatment post-discharge. All participants will receive contingency management in which incentives are given for medication adherence as evaluated by the Medication Events Monitoring System (MEMS). The primary outcome measure is maximum days of continuous cocaine abstinence, as assessed by twice-weekly urine drug screens (UDS) and self-report, during the 15-week outpatient treatment phase. Drug-abuse outcomes include cocaine use as assessed by UDS and self-report of cocaine use, other substance use as assessed by UDS and self-report of substance use (i.e., alcohol and/or illicit drugs), cocaine bingeing, HIV risk behavior, quality of life, functioning, and substance abuse treatment attendance. Unique aspects of the study include conducting an efficacy trial in community treatment programs, a two-stage process to efficiently evaluate buspirone, and an evaluation of mediators by which buspirone might exert a beneficial effect on relapse prevention.

KW - Buspirone

KW - Cocaine

KW - Contingency management

KW - Relapse-prevention

UR - http://www.scopus.com/inward/record.url?scp=84864294070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864294070&partnerID=8YFLogxK

U2 - 10.1016/j.cct.2012.05.003

DO - 10.1016/j.cct.2012.05.003

M3 - Article

VL - 33

SP - 993

EP - 1002

JO - Contemporary Clinical Trials

JF - Contemporary Clinical Trials

SN - 1551-7144

IS - 5

ER -